Florida AG sues Pfizer and CEO over COVID-19 vaccine claims

• Florida claims Pfizer made over $80 billion from vaccine sales and nearly quadrupled the price from $30 per dose to $110-$130 in 2023
• The lawsuit alleges Pfizer urged people to get vaccinated to protect others despite never testing whether the vaccine stopped viral transmission
• The state seeks fines of $10,000 per violation ($15,000 for seniors or disabled individuals), an injunction to stop the alleged conduct, and return of profits under consumer protection law

Florida Sues Pfizer and CEO Over COVID-19 Vaccine Marketing Claims

Florida Attorney General James Uthmeier filed a lawsuit on October 1st against Pfizer and CEO Albert Bourla in state court, alleging the pharmaceutical company misled consumers about the safety and effectiveness of its COVID-19 vaccine.

Key Allegations:

The lawsuit accuses Pfizer of:

• Marketing the vaccine as safe while failing to disclose potential risks, including heart inflammation and other adverse events
• Claiming the vaccine would protect others without testing whether it prevented viral transmission
• Employing unfair tactics to dominate the vaccine market

Financial Claims:

Florida alleges Pfizer generated over $80 billion in vaccine sales and subsequently increased pricing dramatically—nearly quadrupling the cost from $30 per dose to a range of $110-$130 per dose in 2023.

Legal Action:

The state is pursuing the case under consumer protection law and seeks:

• Court order to halt the alleged conduct
• Fines of $10,000 per violation
• Enhanced fines of $15,000 for violations affecting seniors or disabled individuals
• Return of profits from the alleged misconduct

Market Implications:

This lawsuit adds to regulatory and legal scrutiny facing major pharmaceutical companies over COVID-19 vaccine communications. The case could potentially impact Pfizer's reputation and future vaccine pricing strategies, though the company has not yet responded to requests for comment.

The timing coincides with ongoing debates about pharmaceutical pricing transparency and vaccine safety communications, potentially setting precedent for how states regulate drugmaker marketing claims during public health emergencies.